Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 20,248 Ordinary Shares on August 15, 2005. These shares were transferred by Abacus (GSK) Trustees Limited, acting as trustee of the GlaxoSmithKline Employee Trust ("the GSK Trust"), to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
- The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
- Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees.
- The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares transferred (20,248) and the specific date of transfer (August 15, 2005).
- Confirm the identity of the trustee (Abacus (GSK) Trustees Limited) and the specific employee plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Note that this filing does not impact the company's financial statements directly but relates to internal equity compensation movements.